01 mening Loehr 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

10

Download PDF ↗ Live URL (may be dead)

Document text

Introduction to Meningococcal Session
Jamie Loehr, MD
Advisory Committee on Immunization Practices
October 24, 2024National Center for Immunization & Respiratory Diseases
1
23 Terms of Reference
GSK pentavalent ( MenABCWY ) vaccine
–Prescription Drug User Fee Act date for regulatory decision:  
•February 14, 2025
MenB- 4C (Bexsero) FDA interval and dosing change
Revisiting the adolescent meningococcal vaccine schedule 
33 Terms of Reference
GSK pentavalent ( MenABCWY ) vaccine  Vote Feb 2025
–Prescription Drug User Fee Act date for regulatory decision:  
•February 14, 2025
MenB- 4C (Bexsero) FDA interval and dosing change  Vote Oct 2024
Revisiting the adolescent meningococcal vaccine schedule Vote 2025
4GSK Pentavalent ( MenABCWY ) Vaccine
Today:
–Cost -effectiveness
–Evidence to Recommendations Framework ( EtR)
•Includes GRADE
5MenB -4C (Bexsero) FDA Interval and Dosing Change
Today:
–Abridged Evidence to Recommendations ( EtR) Framework
•Cost -effectiveness and GRADE not indicated
–Work Group considerations 
–Vote
0.000.200.400.600.801.001.201.40
1996 2000 2005 2010 2015 2020 2023Incidence per 100,000
YearMeningococcal Disease Incidence –
United States, 1996 –2023*
Abbreviations: MenACWY  vaccine = quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccine; MenB  vaccine = serogroup B meningococcal vaccine
Source: 1996– 2023 NNDSS Data. *2023 NNDSS data are preliminary.0.13 cases/100,000 populationMenACWY vaccine1.2 cases/100,000 
population
MenB  vaccine
6
00.020.040.060.080.10.12
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023Incidence per 100,000
YearB C Y W Other
Source: NNDSS data with additional serogroup data from Active Bacterial Core surveillance (ABCs) and state health departments  
*2023 data are preliminaryTrends in Meningococcal Disease Incidence by 
Serogroup – United States, 2006 –2023*
7
Average Annual Meningococcal Disease Incidence by 
Age Group and Serogroup―United States, 2012 –2021
Source: NNDSS data with additional serogroup data from ABCs and state health departments0.000.100.200.300.400.500.600.700.800.901.00
<1 year 1 year 2-4 years 5-10
years11-15
years16-20
years21-25
years26-44
years45-64
years65-84
years85+
yearsIncidence per 100,000
Age GroupB ACWY Oth/Unk
8
Average Annual Meningococcal Disease Incidence by 
Age Group and Serogroup―United States, 2022 –2023*
Source: NNDSS data with additional serogroup data from ABCs and state health departments
 *2023 NNDSS data are preliminary.0.000.100.200.300.400.500.600.700.800.901.00
<1 year 1 year 2-4 years 5-10
years11-15
years16-20
years21-25
years26-44
years45-64
years65-84
years85+
yearsIncidence per 100,000
Age GroupB ACWY Oth/Unk
9
10ACIP Meningococcal Vaccines Work Group 
 ACIP Members on the WG
 Jamie Loehr (Chair)
 Wilbur Chen
 Charlotte Moser
 Ex Officio WG Members
 Margaret Bash (FDA)
 Matthew Clark (IHS)
 Xin-Xing Gu (NIH)
 WG Liaisons and Consultants
 Amra Resic  (AAFP)
 Mary Healy (AAP) 
 Barb Fluty (ACHA)
 Karyn Lyons (AIM)
 Paul Cieslak (CSTE)
 Kathy Hsu (IDSA)
 Pamela Doyon -Plourde (NACI)
 Jeff Goad (NFID)
 Jessica Cataldi (PIDS)
 Amy Middleman (SAHM)
 Kathy Poehling (Wake Forest)
 Lynn Bahta (Minnesota Department of Health)
 David Stephens (Emory)
 GRADE/ EtR Support
 Doug Campos -Outcalt (Arizona)
 Rebecca Morgan (Case Western Reserve) CDC Contributors
 Sarah Schillie (DBD/NCIRD) – Meningococcal Lead
 Jennifer Collins (DBD/NCIRD) – Hib Lead
 Lucy McNamara (DBD/NCIRD)
 Avnika Amin (DBD/NCIRD)
 LeAnne Fox (DBD/NCIRD)
 Susan Hariri (DBD/NCIRD)
 Amy Rubis (DBD/NCIRD)
 Jennie Thomas (DBD/NCIRD)
 Noele Nelson (DBD/NCIRD)
 Alison Albert (DBD/NCIRD)
 Shelby Miller (DBD/NCIRD)
 Michelle Hughes (DBD/NCIRD)
 Madhura Vachon (DBD/NCIRD)
 Gabrielle Cooper (DBD/NCIRD)
 Xiaoyu Dong (ISD/NCIRD)
 Andrew Leidner (ISD/NCIRD)
 Ismael Ortega- Sanchez (CORVD/NCIRD)
 Marc Fischer (DIDRI/NCEZID)
 Jonathan Duffy (DHQP/NCEZID)
 Pedro Moro (DHQP/NCEZID)
 Tanya Myers (DHQP/NCEZID) 
 Leslie Lee (OD/NCIRD)
 Manisha (Mo) Patel (OD/NCIRD)
 Jessica MacNeil (ACIP Secretariat)
 Hannah Rosenblum (ACIP Secretariat)
 Melinda Wharton (ACIP Secretariat)